SV2A and early-onset autosomal dominant Alzheimer disease: There are now over 100 clinical studies using SV2A PET radiotracers in a wide range of disorders, including neurodegeneration (e.g. Alzheimer’s disease, frontotemporal dementia, supranuclear palsy), psychiatric disorders (e.g. schizophrenia), epilepsy and stroke.